The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people1. Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus2, 3. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B4. Here we describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log10 reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.
At a glance
- Global epidemiology and burden of hepatitis C. Microbes Infect. 4, 1219–1225 (2002)
- Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 355, 2444–2451 (2006) &
- Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J. Gastroenterol. 14, 3621–3627 (2008)
- Challenges and successes in developing new therapies for hepatitis C. Nature 436, 953–960 (2005) &
- Hepatitis C virus replicons: potential role for drug development. Nature Rev. Drug Discov. 1, 911–916 (2002)
- Exploring biology with small organic molecules. Nature 432, 846–854 (2004)
- Cell-based assays to identify inhibitors of viral disease. Exp. Opin. Drug Discov. 3, 671–676 (2008) , , &
- Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110–113 (1999) et al.
- Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49, 1346–1353 (2005) et al.
- Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84, 482–491 (2010) et al.
- Hepatitis C virus NS5A inhibitors. World patent WO-2008021927. (2008) et al.
- Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 78, 7904–7915 (2004) &
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103, 7408–7413 (2006) et al.
- Efficient hepatitis C virus cell culture system: what a difference the host cell makes. Proc. Natl Acad. Sci. USA 102, 9739–9740 (2005) &
- Sensitivity of hepatitis C virus to cyclosporin A depends on nonstructural proteins NS5A and NS5B. Hepatology 46, 1026–1033 (2007) et al.
- NS5A – from obscurity to new target for HCV therapy. Recent Patents Anti-infect. Drug Discov. 3, 77–92 (2008) &
- Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374–379 (2005) , &
- Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83, 4395–4403 (2009) , , , &
- From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 281, 9833–9836 (2006) , , &
- Hepatitis C virus infection. N. Engl. J. Med. 345, 41–52 (2001) &
- The way forward in HCV treatment – finding the right path. Nature Rev. Drug Discov. 6, 991–1000 (2007) et al.
- Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Exp. Opin. Drug Discov. 4, 293–314 (2009) , &
- Specific inhibition of bovine viral diarrhea virus replicase. J. Virol. 77, 6753–6760 (2003) et al.
- Supplementary Information (401K)
This file contains Supplementary Tables S1-S14, Supplementary References and data for Experimental Chemistry.